{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:25:34Z","timestamp":1780323934373,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s12288-018-0966-5","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T06:49:45Z","timestamp":1526539785000},"page":"66-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pegfilgrastim: More Cost Effective and Equally Efficacious Option as Compared to Filgrastim in Autologous Stem Cell Transplant"],"prefix":"10.1007","volume":"35","author":[{"given":"V.","family":"Sheth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ghanekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"key":"966_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(96)90536-X","volume":"347","author":"N Schmitz","year":"1996","unstructured":"Schmitz N, Linch DC, Dreger P et al (1996) Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353\u2013357","journal-title":"Lancet"},{"key":"966_CR2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/0003-4819-126-8-199704150-00002","volume":"126","author":"O Hartmann","year":"1997","unstructured":"Hartmann O, Le Corroller AG, Blaise D et al (1997) Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 126:600\u2013607","journal-title":"Ann Intern Med"},{"key":"966_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.bmt.1701104","volume":"21","author":"C Tarella","year":"1998","unstructured":"Tarella C, Castellino C, Locatelli F et al (1998) G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 21:401\u2013407","journal-title":"Bone Marrow Transplant"},{"key":"966_CR4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1046\/j.1365-2141.1997.4703274.x","volume":"99","author":"DC Linch","year":"1997","unstructured":"Linch DC, Milligan DW, Winfield DA et al (1997) G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 99:933\u2013938","journal-title":"Br J Haematol"},{"key":"966_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.1995.13.6.1323","volume":"13","author":"TR Klumpp","year":"1995","unstructured":"Klumpp TR, Mangan KF, Golderg SL et al (1995) Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 13:1323\u20131327","journal-title":"J Clin Oncol"},{"key":"966_CR6","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/bjc.1998.216","volume":"77","author":"SM Lee","year":"1998","unstructured":"Lee SM, Radford JA, Dobson L et al (1998) Recombinant human granulocyte colony stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin\u2019s lymphoma: clinical benefits at no extra cost. Br J Cancer 77:1294\u20131299","journal-title":"Br J Cancer"},{"key":"966_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/JCO.1994.12.4.661","volume":"12","author":"G Spitzer","year":"1994","unstructured":"Spitzer G, Adkins DR, Spencer V et al (1994) Randomized study of growth factors postperipheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 12:661\u2013670","journal-title":"J Clin Oncol"},{"key":"966_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/bjc.1994.425","volume":"70","author":"DJ Dunlop","year":"1994","unstructured":"Dunlop DJ, Fitzsimons EJ, McMurray A et al (1994) Filgrastim fails to improve haematopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue. Br J Cancer 70:943\u2013945","journal-title":"Br J Cancer"},{"key":"966_CR9","first-page":"4040","volume":"92","author":"Y Kawano","year":"1998","unstructured":"Kawano Y, Takaue Y, Mimaya J et al (1998) Marginal benefit\/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Blood 92:4040\u20134046","journal-title":"Blood"},{"key":"966_CR10","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"key":"966_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00001813-200304000-00002","volume":"14","author":"G Molineux","year":"2003","unstructured":"Molineux G et al (2003) Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 14:259\u2013264","journal-title":"Anticancer Drugs"},{"issue":"Suppl A","key":"966_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0305-7372(02)80002-0","volume":"28","author":"SL Yowell","year":"2002","unstructured":"Yowell SL, Blackwell S et al (2002) Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treatm Rev 28(Suppl A):3\u20136","journal-title":"Cancer Treatm Rev"},{"key":"966_CR13","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/S0301-472X(99)00112-5","volume":"27","author":"G Molineux","year":"1999","unstructured":"Molineux G, Kinstler O, Briddell B et al (1999) A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27:1724\u20131734","journal-title":"Exp Hematol"},{"key":"966_CR14","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2000.18.13.2522","volume":"18","author":"E Johnston","year":"2000","unstructured":"Johnston E, Crawford J, Blackwell S et al (2000) Randomized, dose-escalation study of SD\/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522\u20132528","journal-title":"J Clin Oncol"},{"key":"966_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, Jones SE, O\u2019Shaughnessy J et al (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903\u2013909","journal-title":"Ann Oncol"},{"key":"966_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","volume":"21","author":"JM Vose","year":"2003","unstructured":"Vose JM, Crump M, Lazarus H et al (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21:514\u2013519","journal-title":"J Clin Oncol"},{"key":"966_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O\u2019Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20:727\u2013731","journal-title":"J Clin Oncol"},{"key":"966_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29\u201335","journal-title":"Ann Oncol"},{"key":"966_CR19","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdp576","volume":"21","author":"L Castagna","year":"2009","unstructured":"Castagna L, Bramanti S, Levis A et al (2009) Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 21:1482\u20131485","journal-title":"Ann Oncol"},{"key":"966_CR20","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.bbmt.2009.12.531","volume":"16","author":"A Gerds","year":"2010","unstructured":"Gerds A, Fox-Geiman M et al (2010) Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 16:678\u2013685","journal-title":"Biol Blood Marrow Transplant"},{"key":"966_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3324\/haematol.12081","volume":"93","author":"I Bruns","year":"2008","unstructured":"Bruns I, Steidl U, Fischer JC et al (2008) Pegylated granulocyte colony-stimulating factor mobilizes CD34 cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 93:347\u2013355","journal-title":"Haematologica"},{"key":"966_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/sj.bmt.1704994","volume":"35","author":"MH Jagasia","year":"2005","unstructured":"Jagasia MH, Greer JP, Morgan DS et al (2005) Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 35:1165\u20131169","journal-title":"Bone Marrow Transplant"},{"key":"966_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.exphem.2005.11.013","volume":"34","author":"G Vanstraelen","year":"2006","unstructured":"Vanstraelen G, Frere P, Ngirabacu MC et al (2006) Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 34:382\u2013388","journal-title":"Exp Hematol"},{"key":"966_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1600-0609.2006.00793.x","volume":"78","author":"E Todisco","year":"2007","unstructured":"Todisco E, Castagna L, Sarina B et al (2007) CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. Eur J Haematol 78:111\u2013116","journal-title":"Eur J Haematol"},{"key":"966_CR25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/sj.bmt.1704927","volume":"35","author":"PB Staber","year":"2005","unstructured":"Staber PB, Holub R, Linkesch W et al (2005) Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 35:889\u2013893","journal-title":"Bone Marrow Transplant"},{"key":"966_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.V98.3.579","volume":"98","author":"LF Porrata","year":"2001","unstructured":"Porrata LF, Gertz MA, Inwards DJ et al (2001) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98:579\u2013585","journal-title":"Blood"},{"key":"966_CR27","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/bmt.2009.373","volume":"45","author":"S Mathew","year":"2010","unstructured":"Mathew S, Adel N, Rice RD et al (2010) Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients. Bone Marrow Transplant 45:1522\u20131527","journal-title":"Bone Marrow Transplant"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12288-018-0966-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-018-0966-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-018-0966-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T14:16:21Z","timestamp":1567779381000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12288-018-0966-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,17]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1007\/s12288-018-0966-5","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,17]]},"assertion":[{"value":"11 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Acknowledgement,\u00a0Prof\u00a0Navin Khattry and Prof Arnon Nagler\u00a0for valuable inputs during preparation of manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}